Gilead Sciences, a Fortune 500 US biotechnology company, has announced that it will expand its international operations in Uxbridge.
The announcement comes alongside plans to create a new UK commercial headquarters in Holborn, and to expand its UK research and development headquarters in Cambridge. Together, according to the Mayor of London’s office, this represents an increased investment of £13m and a doubling of Gilead’s UK workforce by the end of 2015 to 600.
The Mayor of London, Boris Johnson said: “London and Boston are two of the greatest scientific cities on the planet and our phenomenal research institutions are collaborating closely to help spur the discovery of new treatments to tackle disease. (This underlines) to the growing importance of the life sciences industry in the UK as we look to ensure that this crucial sector becomes a key contributor to the capital’s growth and health.”